The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer.
作者信息
Mislang Anna Rachelle, Soto-Perez-de-Celis Enrique, Russo Chiara, Colloca Giuseppe, Williams Grant R, O'Hanlon Shane, Cooper Lisa, O'Donovan Anita, Audisio Riccardo A, Cheung Kwok-Leung, Sarrió Regina Gironés, Stauder Reinhard, Jaklitsch Michael, Cairo Clarito, Gil Luiz Antonio, Sattar Schroder, Kantilal Kumud, Loh Kah Poh, Lichtman Stuart M, Brain Etienne, Wildiers Hans, Kanesvaran Ravindran, Battisti Nicolò Matteo Luca
机构信息
Department of Medical Oncology, Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia.
Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
出版信息
J Geriatr Oncol. 2021 Jun;12(5):848-850. doi: 10.1016/j.jgo.2021.03.003. Epub 2021 Mar 5.
Abstract
摘要
相似文献
1
The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer.老年肿瘤患者新冠疫苗接种：国际老年肿瘤学会（SIOG）新冠工作组建议
J Geriatr Oncol. 2021 Jun;12(5):848-850. doi: 10.1016/j.jgo.2021.03.003. Epub 2021 Mar 5.
2
SIOG COVID-19 Working Group recommendations on COVID-19 therapeutic approaches in older adults with cancer.国际老年肿瘤学会（SIOG）COVID-19工作组关于癌症老年患者COVID-19治疗方法的建议。
J Geriatr Oncol. 2023 Jul;14(6):101564. doi: 10.1016/j.jgo.2023.101564. Epub 2023 Jun 23.
3
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.在 COVID-19 大流行期间为老年癌症患者调整护理：国际老年肿瘤学会（SIOG）COVID-19 工作组的建议。
J Geriatr Oncol. 2020 Nov;11(8):1190-1198. doi: 10.1016/j.jgo.2020.07.008. Epub 2020 Jul 16.
4
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
5
An update on the impact of SARS-CoV-2 pandemic public awareness on cancer patients' COVID-19 vaccine compliance: Outcomes and recommendations.SARS-CoV-2 大流行公众意识对癌症患者 COVID-19 疫苗接种依从性影响的最新进展：结果和建议。
Front Public Health. 2022 Jul 22;10:923815. doi: 10.3389/fpubh.2022.923815. eCollection 2022.
6
Changes in attitudes to vaccination as a result of the COVID-19 pandemic: A longitudinal study of older adults in the UK.由于 COVID-19 大流行，人们对疫苗接种的态度发生了变化：对英国老年人的纵向研究。
PLoS One. 2021 Dec 23;16(12):e0261844. doi: 10.1371/journal.pone.0261844. eCollection 2021.
7
COVID-19 vaccinations for patients with cancer: many remain unvaccinated despite having priority in the vaccine rollout.为癌症患者接种新冠疫苗：尽管在疫苗接种计划中享有优先权，但仍有许多患者未接种。
Intern Med J. 2021 Oct;51(10):1760. doi: 10.1111/imj.15497.
8
Challenges facing COVID-19 vaccination in India: Lessons from the initial vaccine rollout.印度新冠疫苗接种面临的挑战：首次疫苗推广的经验教训。
J Glob Health. 2021 Jun 26;11:03083. doi: 10.7189/jogh.11.03083.
9
COVID-19 Vaccine Tweets After Vaccine Rollout: Sentiment-Based Topic Modeling.疫苗接种后关于 COVID-19 疫苗的推文：基于情感的主题建模。
J Med Internet Res. 2022 Feb 8;24(2):e31726. doi: 10.2196/31726.
10
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
引用本文的文献
1
Prevalence and factors of COVID-19 vaccine refusal among solid cancer patients in China: an application of the health belief model.中国实体瘤患者 COVID-19 疫苗拒绝率及其影响因素：健康信念模型的应用。
Front Public Health. 2023 Aug 3;11:1236376. doi: 10.3389/fpubh.2023.1236376. eCollection 2023.
2
The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.在 70 岁以下的癌症患者中，衰老的外周 T 细胞的存在与 COVID-19 疫苗诱导的免疫呈负相关。
Front Immunol. 2023 Jun 2;14:1160664. doi: 10.3389/fimmu.2023.1160664. eCollection 2023.
3
Updated International Society of Geriatric Oncology COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer.老年肿瘤国际协会 COVID-19 工作组关于癌症老年患者 COVID-19 疫苗接种的最新建议
J Geriatr Oncol. 2022 Sep;13(7):1054-1057. doi: 10.1016/j.jgo.2022.07.005. Epub 2022 Jul 15.
4
Elucidating the effect of geriatric parameters on COVID-19 outcomes for older adults with cancer.阐明老年参数对老年癌症患者新冠病毒病结局的影响。
Lancet Healthy Longev. 2022 Mar;3(3):e122-e123. doi: 10.1016/S2666-7568(22)00026-5. Epub 2022 Feb 14.
5
Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center.德国大学肿瘤中心癌症患者中 SARS-CoV-2 抗体血清学阳性率较低。
Oncol Res Treat. 2022;45(3):112-117. doi: 10.1159/000520572. Epub 2021 Nov 1.
6
COVID-19 Vaccine Guidance for Patients with Cancer in Mexico: Report From the Working Group of the Mexican Society of Oncology.墨西哥癌症患者的COVID-19疫苗接种指南：墨西哥肿瘤学会工作组报告
Arch Med Res. 2022 Feb;53(2):223-227. doi: 10.1016/j.arcmed.2021.07.005. Epub 2021 Jul 30.
7
Serological response to COVID-19 vaccination in patients with cancer older than 80 years.80 岁以上癌症患者对 COVID-19 疫苗接种的血清学反应。
J Geriatr Oncol. 2021 Nov;12(8):1253-1255. doi: 10.1016/j.jgo.2021.06.002. Epub 2021 Jun 11.
8
Multi-Level Governance of COVID-19 Pandemic and the Solitude Within Geriatric Oncology.COVID-19大流行的多层次治理与老年肿瘤学中的孤独感
Front Public Health. 2021 Apr 29;9:647444. doi: 10.3389/fpubh.2021.647444. eCollection 2021.
本文引用的文献
1
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
2
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
7
The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019-Missing the Target.《将老年人排除在 2019 年冠状病毒病疫苗和治疗试验之外——错失目标》
JAMA Intern Med. 2020 Nov 1;180(11):1546-1549. doi: 10.1001/jamainternmed.2020.5084.
8
Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5-18, 2020 - 22 States, February-June 2020.2020 年 2 月至 6 月，22 个州，在 2020 年 6 月 5 日至 18 日确定为热点的县中代表性不足的种族/族裔群体中 COVID-19 发病率的差异。
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1122-1126. doi: 10.15585/mmwr.mm6933e1.
9
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.在 COVID-19 大流行期间为老年癌症患者调整护理：国际老年肿瘤学会（SIOG）COVID-19 工作组的建议。
J Geriatr Oncol. 2020 Nov;11(8):1190-1198. doi: 10.1016/j.jgo.2020.07.008. Epub 2020 Jul 16.
10
Effect of the social distancing measures on the spread of COVID-19 in 10 highly infected countries.社交距离措施对 10 个高感染国家 COVID-19 传播的影响。
Sci Total Environ. 2020 Nov 10;742:140430. doi: 10.1016/j.scitotenv.2020.140430. Epub 2020 Jun 22.
Zotero 插件